2007 4 14, Eli Lilly and Boehringer Ingelheim jointly held in Beijing, the latest antidepressants up-to-market will be pleased 100. Lilly China President Ou Taige Dr . Boehringer Ingelheim, Dr . Pang Nabo, general manager of China attended the public meeting and made a speech.
Xin Butterfield (duloxetine hydrochloride) is a Lilly developed new dual transmitter antidepressants (SNRI), in 2004 by the U. S. Food and Drug Administration (FDA) and the European Commission approved the use of in the treatment of adult depression. Xin 100 people can reach two important brain neurotransmitters? Serotonin and norepinephrine to the dual role, to effectively treat the emotional symptoms of depression and somatic symptoms. Xin Bai-da is following the well-known Lilly antidepressant Prozac in the treatment of depression after the introduction of another main product areas. Drug by Lilly and Boehringer Ingelheim worldwide joint marketing, has been approved officially listed in China.
“Depression is a serious mental and physical disorders, the prevalence of global and China showed a rising trend. Existing antidepressant drugs for the treatment of depressive mood symptoms, such as crying, sadness and other effects are more significant than However , for the treatment of physical symptoms in depression is not very good. “branch of Chinese Medical Association, Vice Chairman of Psychiatry, Second Xiangya Hospital, Institute of Mental Health, Professor Zhao Jingping said. “Duloxetine’s dual channel it in effective control mechanisms of emotional symptoms in patients with the same time, can effectively alleviate depression caused by the physical pain, which will bring doctors and patients a better treatment option. ”
Current medical aspects of the depression of body pain diagnosis situation is not optimistic. World Mental Health Federation of the same study showed that physical pain may reduce the rate of depression diagnosis. About 73% of the doctors in the face of pain associated with fear when the misdiagnosis of patients, only 38% of the doctors will think of somatic symptoms is a symptom of depression. Survey shows that current depressive symptoms in the treatment of pain there are serious deficiencies. Only 40% of patients with depression present expressed satisfaction with the efficacy of antidepressants, and only 35% of general practitioners and psychiatrists in 28% of the current expressed satisfaction with the efficacy of antidepressants. Does not relieve pain symptoms will significantly increase the risk of recurrence. Therefore , the treatment of depression associated with pain in the body of a comprehensive treatment for depression is essential. Meanwhile, the earlier the diagnosis and treatment of depression, while treatment of depression and emotional symptoms can be painful physical symptoms of depression may reach clinical cure.
Yan Baida up for the mainstream market for antidepressants in the treatment of somatic pain deficiencies, is a comprehensive new anti-depressant pharmaceutical effect. In effective control of the emotional symptoms of depression, while Yan Baida can effectively relieve pain in patients with somatic symptoms. Furthermore, a balance mechanism, Yan 100 up to the initial dose of treatment that can play a role, without the need to adjust dosage, making treatment more convenient, more patients will certainly bring good news.
Welcomes the end of 2004 reached 100 in the U. S., has listed more than 70 countries around the world. 2006 was its second full year listing, or global sales of 13 billion U. S. dollars, the rapid growth in 2005 nearly doubled in the second full year listing on the break one billion U. S. dollars of this so-called “re- pound bomb, “the threshold of the product in the entire pharmaceutical industry is also extremely rare. In 2006, Yan 100 up in the U. S. market has exceeded all antidepressants, the market share of the fastest growing products.